Dyne Therapeutics Files 8-K, Confirms Emerging Growth Status
Ticker: DYN · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $92.2 m |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, emerging-growth-company, corporate-governance
TL;DR
**Dyne Therapeutics confirmed its emerging growth company status in an 8-K, signaling lighter regulatory burdens.**
AI Summary
Dyne Therapeutics, Inc. filed an 8-K on January 4, 2024, to report an "Other Event." This filing indicates that Dyne Therapeutics is an "emerging growth company" as defined by the SEC. This matters to investors because emerging growth companies often have fewer reporting requirements, which can mean less transparency but also potentially lower compliance costs, impacting the company's operational efficiency and investor due diligence.
Why It Matters
This filing confirms Dyne Therapeutics' status as an emerging growth company, which affects its regulatory obligations and could influence investor perception regarding transparency and growth potential.
Risk Assessment
Risk Level: low — This filing is purely administrative, confirming an existing status, and does not introduce new financial or operational risks.
Analyst Insight
Investors should note Dyne Therapeutics' emerging growth company status, as it implies fewer regulatory disclosures. This means investors may need to conduct more independent research to fully understand the company's financial health and operational risks compared to a fully mature public company.
Key Players & Entities
- Dyne Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 4, 2024 (date) — date of earliest event reported and filing date
- 001-39509 (other) — Commission File Number for Dyne Therapeutics
- DYN (other) — trading symbol for Dyne Therapeutics' common stock
- Nasdaq Global Select Market (other) — exchange where Dyne Therapeutics' common stock is registered
FAQ
What is the purpose of Dyne Therapeutics, Inc.'s 8-K filing dated January 4, 2024?
The 8-K filing by Dyne Therapeutics, Inc. on January 4, 2024, is categorized under 'Other Events' and primarily serves to confirm its status as an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
What is Dyne Therapeutics, Inc.'s trading symbol and on which exchange is its common stock registered?
Dyne Therapeutics, Inc.'s common stock trades under the symbol 'DYN' and is registered on the Nasdaq Global Select Market.
What is the business address and phone number of Dyne Therapeutics, Inc. as stated in the filing?
The business address for Dyne Therapeutics, Inc. is 1560 Trapelo Road, Waltham, Massachusetts, 02451, and its telephone number is (781) 786-8230.
What is the significance of Dyne Therapeutics, Inc. being an 'emerging growth company'?
Being an 'emerging growth company' means Dyne Therapeutics, Inc. qualifies for certain scaled-back disclosure requirements and exemptions from various regulatory provisions under the JOBS Act, which can reduce compliance costs but may also result in less public information for investors.
What is the state of incorporation for Dyne Therapeutics, Inc.?
Dyne Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-01-04 17:12:33
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share DYN Nasdaq Glob
- $92.2 m — es for aggregate gross sale proceeds of $92.2 million, before deducting sales commissio
Filing Documents
- d687857d8k.htm (8-K) — 24KB
- 0001193125-24-002542.txt ( ) — 142KB
- dyn-20240104.xsd (EX-101.SCH) — 3KB
- dyn-20240104_lab.xml (EX-101.LAB) — 18KB
- dyn-20240104_pre.xml (EX-101.PRE) — 11KB
- d687857d8k_htm.xml (XML) — 3KB
01
Item 8.01. Other Events. On January 4, 2024, Dyne Therapeutics, Inc. (the "Company") notified Jefferies LLC ("Jefferies") that it was suspending and terminating the prospectus, dated November 17, 2021 (the "ATM Prospectus"), related to the sales agreement (the "Sales Agreement") that the Company entered into with Jefferies on November 4, 2021 and pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the "Common Stock"), from time to time through Jefferies, as agent, under an "at-the-market" offering program. The Company will not make any sales of its Common Stock pursuant to the Sales Agreement unless and until a new prospectus is filed. The Sales Agreement remains in full force and effect. As of January 4, 2024, the Company had issued and sold an aggregate of 7,943,148 shares of its Common Stock under its "at-the-market" offering program with Jefferies for aggregate gross sale proceeds of $92.2 million, before deducting sales commissions and offering expenses. A copy of the Sales Agreement was filed as Exhibit 1.2 to the Company's Registration Statement on Form S-3 (333- 260755), which was originally filed with the Securities and Exchange Commission on November 4, 2021.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DYNE THERAPEUTICS, INC. Date: January 4, 2024 By: /s/ Joshua Brumm Name: Joshua Brumm Title: President and Chief Executive Officer